We bring you our round-up of the latest legal and commercial issues for life sciences businesses.
In this issue we outline the MHRA's new guidance on post-Brexit medical regulation in the UK. We also look at the government’s recent “Call for Views” exploring whether the UK IP framework remains fit for purpose in relation to AI.
A link to the web version of this email update is available here. If you would like to receive these updates via email, please subscribe.
Charlotte Tillett
Gustaf Duhs